DDInter686 DDInter298
A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Etacrynic acid {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Etacrynic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Etacrynic acid {u} (Compound) upregulates {v} (Gene) CDKN1A
CDKN1A {u} (Gene) is associated with {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Etacrynic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Esomeprazole
Esomeprazole {u} (Compound) palliates {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Etacrynic acid {u} (Compound) upregulates {v} (Gene) GCLM
GCLM {u} (Gene) is upregulated by {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Etacrynic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Esomeprazole
Esomeprazole {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Etacrynic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Etacrynic acid {u} (Compound) downregulates {v} (Gene) LIG1
LIG1 {u} (Gene) is associated with {v} (Disease) urinary bladder cancer
urinary bladder cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Etacrynic acid {u} (Compound) upregulates {v} (Gene) FAS
FAS {u} (Gene) is regulated by {v} (Gene) NQO1
NQO1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Etacrynic acid {u} (Compound) downregulates {v} (Gene) LIG1
LIG1 {u} (Gene) is regulated by {v} (Gene) ABCC2
ABCC2 {u} (Gene) is bound by {v} (Compound) Carboplatin
Etacrynic acid (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Carboplatin (Compound)
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Etacrynic acid (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is associated with esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole (Compound) palliates esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Etacrynic acid (Compound) upregulates GCLM (Gene) and GCLM (Gene) is upregulated by ovarian cancer (Disease) and ovarian cancer (Disease) is treated by Carboplatin (Compound)
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Carboplatin (Compound)
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is bound by Carboplatin (Compound)
Etacrynic acid (Compound) downregulates LIG1 (Gene) and LIG1 (Gene) is associated with urinary bladder cancer (Disease) and urinary bladder cancer (Disease) is treated by Carboplatin (Compound)
Etacrynic acid (Compound) upregulates FAS (Gene) and FAS (Gene) is regulated by NQO1 (Gene) and NQO1 (Gene) is bound by Carboplatin (Compound)
Etacrynic acid (Compound) downregulates LIG1 (Gene) and LIG1 (Gene) is regulated by ABCC2 (Gene) and ABCC2 (Gene) is bound by Carboplatin (Compound)